(CI) Cigna - Overview

Sector: Healthcare | Industry: Healthcare Plans | Exchange: NYSE (USA) | Market Cap: 71.021m USD | Total Return: -19.9% in 12m

Stock Health Insurance, Pharmacy Benefits, Senior Plans, International Coverage
Total Rating 48
Risk 76
Buy Signal -0.97
Healthcare Plans +4.6
Health Care Services +4.7
Market Cap: 71,021m
Avg Trading Vol: 507M USD
ATR: 2.80%
Peers RS (IBD): 35.0
Risk 5d forecast
Volatility37.3%
Rel. Tail Risk-20.2%
Reward TTM
Sharpe Ratio-0.60
Alpha-24.97
Character TTM
Beta0.221
Beta Downside0.159
Drawdowns 3y
Max DD32.10%
CAGR/Max DD0.04
EPS (Earnings per Share) EPS (Earnings per Share) of CI over the last years for every Quarter: "2021-03": 4.73, "2021-06": 5.24, "2021-09": 5.73, "2021-12": 4.77, "2022-03": 6.01, "2022-06": 6.22, "2022-09": 6.04, "2022-12": 4.96, "2023-03": 5.41, "2023-06": 6.13, "2023-09": 6.77, "2023-12": 6.79, "2024-03": 6.47, "2024-06": 6.72, "2024-09": 7.51, "2024-12": 6.64, "2025-03": 6.74, "2025-06": 7.2, "2025-09": 7.83, "2025-12": 8.08,
EPS CAGR: 8.21%
EPS Trend: 78.6%
Last SUE: 0.35
Qual. Beats: 0
Revenue Revenue of CI over the last years for every Quarter: 2021-03: 40971, 2021-06: 43131, 2021-09: 44288, 2021-12: 45768, 2022-03: 44006, 2022-06: 45478, 2022-09: 45281, 2022-12: 45751, 2023-03: 46517, 2023-06: 48586, 2023-09: 49048, 2023-12: 51114, 2024-03: 57255, 2024-06: 60523, 2024-09: 63694, 2024-12: 65649, 2025-03: 65502, 2025-06: 67230, 2025-09: 69748, 2025-12: 72472,
Rev. CAGR: 14.23%
Rev. Trend: 97.7%
Last SUE: 3.48
Qual. Beats: 12
Description: CI Cigna March 05, 2026

Cigna Group (CI) operates in the United States, providing insurance and health-related products and services.

The Evernorth Health Services segment delivers pharmacy benefits, specialty pharmacy, and care management solutions. This segment primarily serves health plans, employers, and government organizations, a common business model for pharmacy benefit managers (PBMs).

The Cigna Healthcare segment offers medical, pharmacy, and dental insurance to both insured and self-insured customers, including Medicare plans. This segment also provides international health coverage, a strategy for diversifying risk and expanding market reach.

Cigna distributes its offerings through brokers, consultants, and direct sales. For a deeper dive into CIs financial health and market position, consider exploring ValueRay.

Headlines to Watch Out For
  • Evernorth PBM growth boosts Cignas service revenue
  • Healthcare medical cost trends impact insurance profitability
  • Government healthcare policy changes create regulatory risk
  • Commercial enrollment fluctuations affect premium income
Piotroski VR‑10 (Strict, 0-10) 5.0
Net Income: 5.96b TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.43 > 1.0
NWC/Revenue: -3.10% < 20% (prev -3.69%; Δ 0.58% < -1%)
CFO/TA 0.06 > 3% & CFO 9.60b > Net Income 5.96b
Net Debt (23.79b) to EBITDA (11.98b): 1.99 < 3
Current Ratio: 0.85 > 1.5 & < 3
Outstanding Shares: last quarter (265.9m) vs 12m ago -4.26% < -2%
Gross Margin: 9.45% > 18% (prev 0.11%; Δ 934.6% > 0.5%)
Asset Turnover: 175.2% > 50% (prev 158.5%; Δ 16.71% > 0%)
Interest Coverage Ratio: 6.77 > 6 (EBITDA TTM 11.98b / Interest Expense TTM 1.38b)
Altman Z'' 1.44
A: -0.05 (Total Current Assets 47.81b - Total Current Liabilities 56.34b) / Total Assets 157.92b
B: 0.30 (Retained Earnings 47.87b / Total Assets 157.92b)
C: 0.06 (EBIT TTM 9.35b / Avg Total Assets 156.90b)
D: 0.39 (Book Value of Equity 45.06b / Total Liabilities 116.05b)
Altman-Z'' Score: 1.44 = BB
Beneish M -2.81
DSRI: 1.07 (Receivables 28.77b/24.07b, Revenue 274.95b/247.12b)
GMI: 1.11 (GM 9.45% / 10.51%)
AQI: 0.99 (AQ_t 0.67 / AQ_t-1 0.68)
SGI: 1.11 (Revenue 274.95b / 247.12b)
TATA: -0.02 (NI 5.96b - CFO 9.60b) / TA 157.92b)
Beneish M-Score: -2.81 (Cap -4..+1) = A
What is the price of CI shares? As of March 31, 2026, the stock is trading at USD 258.08 with a total of 2,392,587 shares traded.
Over the past week, the price has changed by -1.30%, over one month by -10.46%, over three months by -6.14% and over the past year by -19.90%.
Is CI a buy, sell or hold? Cigna has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy CI.
  • StrongBuy: 13
  • Buy: 6
  • Hold: 6
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CI price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 338.8 31.3%
Analysts Target Price 338.8 31.3%
CI Fundamental Data Overview March 26, 2026
P/E Trailing = 11.9923
P/E Forward = 8.6655
P/S = 0.2584
P/B = 1.6614
P/EG = 0.7633
Revenue TTM = 274.95b USD
EBIT TTM = 9.35b USD
EBITDA TTM = 11.98b USD
Long Term Debt = 30.87b USD (from longTermDebt, last quarter)
Short Term Debt = 592.0m USD (from shortTermDebt, last quarter)
Debt = 31.46b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.79b USD (from netDebt column, last quarter)
Enterprise Value = 94.81b USD (71.02b + Debt 31.46b - CCE 7.68b)
Interest Coverage Ratio = 6.77 (Ebit TTM 9.35b / Interest Expense TTM 1.38b)
EV/FCF = 11.30x (Enterprise Value 94.81b / FCF TTM 8.39b)
FCF Yield = 8.85% (FCF TTM 8.39b / Enterprise Value 94.81b)
FCF Margin = 3.05% (FCF TTM 8.39b / Revenue TTM 274.95b)
Net Margin = 2.17% (Net Income TTM 5.96b / Revenue TTM 274.95b)
Gross Margin = 9.45% ((Revenue TTM 274.95b - Cost of Revenue TTM 248.97b) / Revenue TTM)
Gross Margin QoQ = 7.66% (prev 8.52%)
Tobins Q-Ratio = 0.60 (Enterprise Value 94.81b / Total Assets 157.92b)
Interest Expense / Debt = 1.06% (Interest Expense 335.0m / Debt 31.46b)
Taxrate = 24.25% (395.0m / 1.63b)
NOPAT = 7.08b (EBIT 9.35b * (1 - 24.25%))
Current Ratio = 0.85 (Total Current Assets 47.81b / Total Current Liabilities 56.34b)
Debt / Equity = 0.75 (Debt 31.46b / totalStockholderEquity, last quarter 41.71b)
Debt / EBITDA = 1.99 (Net Debt 23.79b / EBITDA 11.98b)
Debt / FCF = 2.84 (Net Debt 23.79b / FCF TTM 8.39b)
Total Stockholder Equity = 40.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.80% (Net Income 5.96b / Total Assets 157.92b)
RoE = 14.53% (Net Income TTM 5.96b / Total Stockholder Equity 40.99b)
RoCE = 13.01% (EBIT 9.35b / Capital Employed (Equity 40.99b + L.T.Debt 30.87b))
RoIC = 9.75% (NOPAT 7.08b / Invested Capital 72.67b)
WACC = 4.93% (E(71.02b)/V(102.48b) * Re(6.76%) + D(31.46b)/V(102.48b) * Rd(1.06%) * (1-Tc(0.24)))
Discount Rate = 6.76% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -4.98%
[DCF] Terminal Value 86.08% ; FCFF base≈8.62b ; Y1≈8.40b ; Y5≈8.47b
[DCF] Fair Price = 867.7 (EV 252.56b - Net Debt 23.79b = Equity 228.77b / Shares 263.7m; r=6.0% [WACC]; 5y FCF grow -3.56% → 3.0% )
EPS Correlation: 78.55 | EPS CAGR: 8.21% | SUE: 0.35 | # QB: 0
Revenue Correlation: 97.74 | Revenue CAGR: 14.23% | SUE: 3.48 | # QB: 12
EPS next Quarter (2026-06-30): EPS=7.39 | Chg7d=+0.002 | Chg30d=-0.057 | Revisions Net=-3 | Analysts=22
EPS current Year (2026-12-31): EPS=30.34 | Chg7d=+0.007 | Chg30d=+0.048 | Revisions Net=+4 | Growth EPS=+1.7% | Growth Revenue=+2.9%
EPS next Year (2027-12-31): EPS=33.48 | Chg7d=+0.022 | Chg30d=+0.010 | Revisions Net=+3 | Growth EPS=+10.4% | Growth Revenue=+5.8%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -0.4% (Discount Rate 7.9% - Earnings Yield 8.3%)
[Growth] Growth Spread = +4.4% (Analyst 4.0% - Implied -0.4%)
Additional Sources for CI Stock Fund Manager Positions: Dataroma · Stockcircle